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Abstract Chronic obstructive lung diseases are char-
acterized by the inability to prevent bacterial infection
and a gradual loss of lung function caused by recurrent
inﬂammatory responses. In the past decade, numerous
studies have demonstrated the importance of nucleo-
tide-mediated bacterial clearance. Their interaction
with P2 receptors on airway epithelia provides a rapid
Fon-and-off_ signal stimulating mucus secretion, cilia
beating activity and surface hydration. On the other
hand, abnormally high ATP levels resulting from
damaged epithelia and bacterial lysis may cause lung
edema and exacerbate inﬂammatory responses. Air-
way ATP concentrations are regulated by ecto nucle-
osidetriphosphatediphosphohydrolases(E-NTPDases)
whichareexpressedonthemucosalsurfaceandcatalyze
the sequential dephosphorylation of nucleoside tri-
phosphates to nucleoside monophosphates (ATP Y
ADP Y AMP). The common bacterial product,
Pseudomonas aeruginosa lipopolysaccharide (LPS),
induces an acute reduction in azide-sensitive E-
NTPDase activities, followed by a sustained increase
in activity as well as NTPDase 1 and NTPDase 3
expression. Accordingly, chronic lung diseases, includ-
ing cystic ﬁbrosis (CF) and primary ciliary dyskinesia,
are characterized by higher rates of nucleotide elimi-
nation, azide-sensitive E-NTPDase activities and ex-
pression. This review integrates the biphasic regulation
of airway E-NTPDases with the function of purine
signaling in lung diseases. During acute insults, a
transient reduction in E-NTPDase activities may be
beneﬁcial to stimulate ATP-mediated bacterial clear-
ance. In chronic lung diseases, elevating E-NTPDase
activities may represent an attempt to prevent P2
receptor desensitization and nucleotide-mediated lung
damage.
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Abbreviations
ADP adenosine 50-diphosphate
AMP adenosine 50-monophosphate
ATP adenosine 50-triphosphate
ASL airway surface liquid
MCC mucociliary clearance
CCS cyclic compressive stress
CF cystic ﬁbrosis
CFTR cystic ﬁbrosis transmembrane regulator
ENAC epithelial sodium channel
IL-1b interleukin-1beta
IL-8 interleukin-8
LPS lipopolysaccharide
MCC mucociliary clearance
NS AP non-speciﬁc alkaline phosphatase
PCL periciliary liquid
PCR polymerase chain reaction
TNFa tumor necrosis factor alpha
UTP uridine 50-triphosphate
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Airway epithelia constitute an essential protective
barrier against lung infection, coordinating luminal
and interstitial responses to inhaled pathogens through
signals (growth factors, cytokines and nucleotides)
provided by epithelial, inﬂammatory and immune cells
[1]. It is now widely accepted that extracellular nucleo-
tides provide an elaborated cell communication system
in mammalian tissues [2, 3] including the airways [4, 5].
Each signaling event constitutes a brief Fon-and-off_
switch mechanism allowing the target cells to perceive
the subsequent signal. The major source of extracellu-
lar nucleotides in normal airways is the epithelium,
releasing ATP under resting conditions and in re-
sponse to mechanical or osmotic stress [6]. While basal
ATP concentrations maintained under resting condi-
tions are insufﬁcient to activate surface receptors, the
levels reached near the site of stimulated release
initiate a variety of P2 receptor-mediated responses
[7]. Two P2 receptor families have been identiﬁed:
Fast-acting (ionotropic) P2X ligand-gated cation chan-
nels and slow-acting (metabotropic) G protein-coupled
P2Y receptors [8]. Although ATP activates members
of both families, P2X receptors generally respond to
higher concentrations (EC50 = 1–10 mM) than P2Y
receptors (EC50 = 0.1–1.0 mM). Each signal is promptly
terminated by surface conversion of ATP to adenosine
[9, 10] and dispersal into the interstitial ﬂuid. Adeno-
sine also initiates cellular responses through P1 (A1,
A2A,A 2B or A3) surface receptors [11]. In the airways,
nucleotide- and adenosine-mediated communications
are involved in wound healing [4], bacterial clearance
[12] and inﬂammatory responses [1, 3, 13, 14].
Cell surface nucleotide concentrations are regulated
by three families of ectonucleotidases in mammalian
tissues: Ecto-nucleotide pyrophosphatase/phospho-
diesterases (E-NPPs: ATP Y AMP), alkaline phos-
phatases (APs: ATP Y AMP Y AMP Y adenosine)
and ecto-nucleoside triphosphate diphosphohydrolases
(E-NTPDases: ATP Y AMP Y AMP) [15]. This
review describes the importance of regulating extracel-
lular nucleotide concentrations for airway homeostasis
andtheimpactofchroniclungdiseasesonE-NTPDases.
Few studies have addressed the activity or expression of
airway E-NTPDases. In this review, the available
information is complemented by original data.
Nucleotide-mediated bacterial clearance
The importance of purine signaling in the airways is
well illustrated in nucleotide-mediated mucociliary
clearance (MCC), which constitutes the ﬁrst line of
defense against bacterial infection [16]. Mucosal epi-
thelial surfaces are protected by an airway surface
liquid (ASL) layer containing a thin mucin sheath
kept above the cilia by a periciliary liquid (PCL)
layer (Fig. 1). Inhaled bacteria adhere to the mucin
and are continuously displaced upward by coordinated
cilia beating activity [17, 18]. Comparative analysis of
the bioelectric properties of airway epithelia from
normal donors and CF patients revealed that PCL
height is regulated by a delicate balance between
the activities of the epithelial sodium channel (ENAC)
andthecysticﬁbrosistransmembraneregulator(CFTR)
[19]. Cystic ﬁbrosis is characterized by mutations in the
gene encoding CFTR [16]. The lack of ion secretion
through CFTR is associated with Na
+ hyperabsorption
by ENAC and water inﬂux, resulting in the depletion
of the PCL layer essential for cilia beating activity. The
cilia become collapsed under a thick layer of mucus
ﬁlled with bacteria and leukocytes, leading to severe
inﬂammatory responses and progressive loss of lung
function.
Extracellular nucleotides and nucleosides regulate
CFTR and ENAC [20]. The basal activity of CFTR is
maintained by adenosine (A2B) receptors, which
induce G protein-coupled adenylate cyclase, followed
by cAMP-dependent activation of type II protein
kinase A [5]. In contrast, ATP stimulates Cl
j secretion
through Ca
2+-activated Cl
j channels. This signaling
pathway involves P2Y2 receptors, leading to G pro-
tein-coupled phospholipase C activation and cyto-
solic Ca
2+ mobilization. Water efﬂux is also stimulated
by P2Y2 receptor-mediated inhibition of Na
+ absorp-
tion by ENAC using Ca
2+-dependent signaling path-
ways [21]. Members of the P2X receptor family also
support luminal Cl
j/water efﬂux in human airway
Fig. 1 Impact of chronic obstructive lung diseases on mucociliary
clearance. The polarized epithelium is composed of columnar
(ciliated or mucin-secreting) cells facing the lumen and basal
cells facing the serosal compartment. Bacterial clearance in
healthy lungs is maintained by coordinated cilia beating activity
within the PCL layer, moving upward the overlying mucus and
pathogens. In chronic obstructive lung diseases, cilia are
collapsed under a thick layer of mucus containing bacteria and
leukocytes.
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lines (Beas2B, 16HBE14o
j, Calu-3, (~CFTE-29o
j)b y
Ussing chamber and patch-clamp experiments [22].
The receptors identiﬁed in airway epithelia by RT–
PCR were P2X2,P 2 X 4 and P2X5. These non-selective
cation channels allow Ca
2+ inﬂux, which then stim-
ulates Ca
2+-activated Cl
j channels. Interestingly, P2X7
receptors are only detected in CF airway epithelia,
primarily in nasal polyps [22]. Because they are known
to induce apoptosis in response to high ATP concen-
trations [23], P2X7 receptors may contribute to dis-
ease-associated epithelial damage.
The central role of ASL nucleotides for MCC was
further substantiated by the observation that P2Y2
receptor activation constitutes the most potent stimu-
lus for cilia beating activity [24–26]a n dm u c i n
secretion [27, 28]. In cultured CF airway epithelia,
P2Y2 receptor activation restores normal PCL height
and rotational mucus transport [29]. Based on these
ﬁndings, aerosolized nucleotides were proposed for the
treatment of chronic obstructive lung diseases [16].
However, clinical studies showed that patients with
asthma or chronic obstructive pulmonary disease
exposed to aerosolized metabolites of ATP (AMP
and adenosine) experience coughing and bronchocon-
striction [30, 31]. Furthermore, aerosolized ATP (not
adenosine) induced similar reactions from healthy
subjects [32, 33]. In developing nucleotide-mediated
MCC therapies, the equally potent P2Y2 receptor
agonist, UTP, was evaluated [6]. Airway clearance in
sheep, measured with nebulized technetium-labeled
albumin, was transiently increased by UTP [34].
Aerosolized UTP also improved MCC in patients with
mild chronic bronchitis [35], CF [36, 37] and primary
ciliary dyskinesia [38].
A major obstacle to the treatment of chronic lung
diseases with aerosolized UTP is the rapid disappear-
ance of therapeutic concentrations (0.1 mM) from the
ASL layer (<5 min) [10, 29]. Incidentally, the meta-
bolically stable UTP analogs INS365 (diquafosol) and
INS37217 (denufosol) developed by Inspire Pharma-
ceuticals Inc. [39] were reported to improve cough
induced-sputum clearance in CF patients [40, 41].
However, long-term treatments with these drugs may
require dose optimization to minimize P2Y2 receptor
desensitization [42].
P2 receptors and airway inﬂammation
In vivo studies conducted on the injurious effects of
mechanical ventilation demonstrated that endogenous
ATP may reach ASL concentrations sufﬁciently high
to trigger inﬂammatory responses and lung damage in
the absence of infection [43]. The bronchoalveolar
lavage ﬂuid of rats subjected to positive-pressure
mechanical ventilation contains signiﬁcantly higher
protein, ATP and cytokine (IL-6, TNFa) levels than
control animals. Instillation of an equivalent ATP
concentration increased lung ﬂuid volume, supporting
the existence of P2 and/or P1 receptor-mediated lung
edema [43]. Analysis of bronchoalveolar lavage ﬂuid
nucleotide content by etheno-derivatization revealed
an increase in AMP + adenosine/ADP + ATP ratio
[44], suggesting that mechanical ventilation up-regu-
lates airway ectonucleotidases. Real-time PCR on
total lung tissue indicated that mechanical ventilation
increases A2B, but decreases P2X7, receptor expres-
sion. Rats subjected to both mechanical ventilation
and positive end-expiratory pressure exhibited normal
bronchoalveolar lavage composition and receptor ex-
pression. These ﬁndings suggest that patients subjected
topositive end-expiratorypressureduringlarge-volume
ventilation may avoid ATP-mediated lung injuries. On
the other hand, the fact that adenosine levels and A2B
receptor expression were raised, whereas ATP levels
and P2X7 receptor expression were decreased, by me-
chanical ventilation supports a dynamic role for
ectonucleotidases in the regulation of purine signaling
in the airways.
The role of P2 receptors in innate defense against
bacterial infection was investigated using mice deﬁ-
cient in P2Y1, P2Y2 or both receptors [45]. All these
mice exhibited lower survival and lower cytokine
levels in lung homogenates than wild-type animals
measured 24 h after intranasal instillation of P.
aeruginosa. These results suggest a protective role for
ATP-induced inﬂammation [45]. In human airways,
P2Y2 receptor activation ampliﬁed inﬂammatory
responses to bacterial infection. Primary cultures of
bronchial epithelial cells exposed to UTP and sputum
from CF patients exhibited an eight-fold increase in
IL-8 secretion, compared to two-fold with UTP alone
[46]. Furthermore, P2X7 receptors are known to
support several processes relevant to inﬂammation,
including LPS neutralization [47], pathogen killing,
nitric oxide production [1] and cytokine release from
mast cells, leukocytes, dendritic cells and neurons [3,
14]. In human blood, LPS-induced IL-1b release is
increased 5-fold by P2X7 receptor activation [48].
Altogether, these studies entail that P2 receptor
activation may not only induce innate immunity
but also amplify pathogen-induced inﬂammatory
responses in chronic infectious lung diseases.
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Excessive inﬂammatory response to recurrent bacte-
rial infection is a major component in the pathogenesis
of chronic lung diseases, irreversibly damaging the
airways and leading to bronchiectasis and respiratory
failure [49–51]. With respect to purine signaling,
nucleotide-mediated cell communications may be
overwhelmed by massive ATP release from cell lysis
of bacteria and damaged epithelia, as well as stimulat-
ed leukocytes and epithelia [6]. The sensitivity of
certain P2 receptors (P2Y2 [42], P2X1 and P2X3 [52])
to agonist-induced desensitization may reduce the
efﬁciency of nucleotide-mediated MCC [53]. On the
other hand, chronically elevated ATP may recruit
signaling pathways normally dormant in healthy lungs.
For instance, P2X7 receptor activation only induces
cytokine release and cell death in response to high
ATP concentrations encountered in damaged tissues
[23]. On astrocytes, LPS-induced TNFa secretion is
increased by P2Y receptor activation at low micro-
molar ATP, but reduced by P2X7 receptor activation
at high ATP concentrations [54]. The authors propose
a beneﬁcial effect for the potentiation of TNFa se-
cretion by P2Y receptors during mild or acute inﬂam-
mation and a protective role for P2X7 receptors in
damaged tissues or chronic infectious diseases. These
studies suggest that P2X7 receptor-mediated responses
may be tissue-speciﬁc and/or inﬂuenced by bacterial
infections. In the respiratory system, P2Y2 receptors
are expressed throughout airway epithelia [39] while
P2X7 receptors have only been reported in nasal
polyps of CF patients [22]. The impact of P2X and
P2Y receptor activation on inﬂammatory responses
mediated by airway epithelia under normal and
pathological conditions remains to be investigated.
E-NTPDases regulate airway ATP
Several studies demonstrate the presence of ectonu-
cleotidase activities on human airway epithelia [9, 10,
55–58]. Time-course experiments conducted on polar-
ized primary cultures of human bronchial epithelial
cells showed that mucosal ATP is dephosphorylated
into ADP, AMP and adenosine (Fig. 2a). Experiments
repeated with nasal, bronchial and bronchiolar epi-
thelial cultures indicated that ATP metabolism accel-
erates toward the alveolar region (Fig. 2b). Such
gradient distribution was also reported for non-speciﬁc
alkaline phosphatase (NS AP) in human airways [9],
an ectonucleotidase capable of sequentially dephos-
phorylating ATP to adenosine [59]. However, com-
plete inhibition of NS AP with 10 mM levamisole [9]
only reduced by 25% total ectoATPase activities [10].
Other ATP-regulating ectonucleotidases were iden-
tiﬁed in mammalian tissues as members of the E-
NTPDase family [15, 60]. They catalyze the hydrolysis
of g- and/or b-phosphate residues, resulting in the for-
mation of nucleoside monophosphates. Their activities
are Ca
2+ and Mg
2+-dependent and insensitive to in-
hibitors of P-, F- and V-type ATPases or APs [61]. Four
E-NTPDases are localized to cell surfaces: NTPDase
1, 2, 3 and 8. Functional studies showed that NTPDase
1[ 62] and NTPDase 3 [63] are inhibited by azide,
whereas NTPDase 2 [64] and NTPDase 8 [65] are
insensitive. The mRNA expression of NTPDase 1, 2
and 3 in human airways was reported in total lung
RNA [66] and cultured bronchial epithelial cells [67].
We now provide evidence that NTPDase 1 and
NTPDase 3 are both expressed throughout human
airways by real-time PCR on freshly excised epithelial
cells (Fig. 3). Their expression distribution followed
surface ectoATPase activities (Fig. 2b), exhibiting
higher mRNA levels in smaller airways (Fig. 3). The
fact that 20 mM azide reduced total ectoATPase
activities by 45% on human bronchial epithelial cells
[67] suggests that the high afﬁnity (Km <1 5mM) [68]
NTPDases 1 and/or 3 play major roles in the regula-
tion of physiological ASL nucleotide concentrations.
The physiological importance of azide-sensitive E-
NTPDases for nucleotide-mediated MCC was recently
established using an in vitro model of rhythmic
Fig. 2 Ectonucleotidases regulate nucleotide concentrations on
airway epithelial surfaces. a Polarized primary cultures of human
bronchial epithelial cells were assayed with 100 mM ATP added
to the mucosal surface, as we previously described [10]. Buffer
sample analysis by high-pressure liquid chromatography (10)
shows that exogenous ATP (&) is dephosphorylated into ADP
(Í), AMP (r) and adenosine ()). b Similar experiments
repeated on primary cultures of human nasal, bronchial and
bronchiolar epithelial cells show that the elimination rate of
ATP increases toward alveoli (N =3 ,* ,P < 0.05; Mann–Whitney
test).
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to mechanical stress generated by breathing, coughing
or chest movement. Since mechanical stress induces
epithelial ATP release [6], static culture conditions
may underestimate the lungs capacity to regulate MCC
in vivo. Rhythmic pressure changes mimicking normal
tidal breathing were reproduced in vitro by a system
applying cyclic compressive stress (CCS) to the muco-
sal surface of primary bronchial epithelial cultures
[69]. Whereas CF cultures under static conditions
exhibit a depleted PCL layer and mucostasis, CCS
mimicking normal tidal breathing (20 cmH2O; 15
cycles/min) restored normal PCL height and mucus
transport through ATP release and P2Y2 receptor
activation. These results also suggest that purine
signaling may provide an explanation for the beneﬁcial
effects of oscillatory therapeutic devices clinically used
to stimulate sputum clearance [70].
Cyclic compressive stress also enhances MCC
through a reduction in ASL nucleotide metabolism.
We recently demonstrated that CCS decreases the rate
of ATP hydrolysis on the mucosal surface of normal
and CF bronchial epithelial cultures [67]. More im-
portantly, CCS restored normal ectoATPase activities
on CF epithelial surfaces. The inhibitory effect of CCS
on ATP metabolism was abrogated by 20 mM azide,
indicating that E-NTPDase 1 and/or E-NTPDase 3
are key components in the regulation P2 receptor-
mediated MCC. Perhaps the ability of CF airway
epithelia to provide adequate nucleotide-mediated
MCC under conditions mimicking normal breathing
may contribute to the relatively healthy state of young
patients before the establishment of chronic infection
[71].
Chronic lung diseases shorten the signals
Recent studies demonstrate that chronic lung diseases
accelerate all metabolic steps supporting the mucosal
conversion of ATP to adenosine [10, 72]. We identiﬁed
the ectonucleotidases involved using primary bronchial
epithelial cultures from healthy donors and patients
with primary ciliary dyskinesia, CF or a1-antitrypsin
deﬁciency. All airway diseases were characterized
by a two- to four-fold increase in the elimination rate
of ATP on the mucosal surface, without signiﬁcant
effect on the serosal surface (Fig. 4). Selective in-
hibitors of NS AP (10 mM levamisole), NTPDase 1
and NTPDase 3 (20 mM azide) partially restored
normal activity levels. However, the lower substrate
afﬁnities of airway NS AP (36 mM and 717 mM) [9]
suggest that NTPDase 1 and/or NTPDase 3 are
responsible for the accelerated clearance of P2 recep-
tor agonists in diseased airways.
Pseudomonas aeruginosa is among the most fre-
quently isolated pathogens from the airways of
patients with gram-negative infections [51]. In patients
with damaged airways from mechanical ventilation,
trauma or viral infection, airway colonization by P.
aeruginosa is often followed by pneumonia, sepsis and
death. Much of the airway inﬂammation induced by
these organisms is caused by released bacterial prod-
ucts adhering to the epithelial surface, such as LPS.
The contribution of bacterial infection to the deregu-
lation of E-NTPDase activities in lung diseases was
Fig. 3 Expression level of NTPDase 1 and NTPDase 3 along
human airways. Total RNA from excised epithelia was analyzed
by real-time PCR using SYBR green assays and normalized to
the expression level of the house-keeping gene, 18S, as we
previously described [89]. The mRNA level of E-NTPDase 1 (Ì)
and NTPDase 3 (Í) increases toward alveoli (N =4 ,* ,P < 0.05;
Mann–Whitney test).
Fig. 4 Chronic lung diseases enhance azide-sensitive E-
NTPDases. Primary bronchial epithelial cultures from healthy
donors (N) and patients diagnosed with primary ciliary dyskine-
sia (PCD), CF or a1-antitrypsin deﬁciency (! AT) were assayed
with bilateral 1 mM ATP in the absence (Í) or presence (Ì)o f
20 mM azide, as we previously described [10]. Analysis of buffer
samples by high-pressure liquid chromatography showed that
azide-sensitive E-NTPDases are concentrated on the mucosal
surface under normal and pathological conditions (N =4 ,* ,P <
0.05; Mann–Whitney test).
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human bronchial epithelial cells exposed 24 h on the
mucosal surface to an optimum LPS concentration
(100 ng/ml) [73] exhibited a biphasic response over
time (Fig. 5A). Azide-sensitive E-NTPDases were
transiently reduced over 8 h, without affecting mRNA
expression. In contrast, prolonged exposures (24 h)
raised the activities two-fold above control levels and
increased NTPDase 1 and NTPDase 3 expression by 4
and 10-fold (Fig. 5B). These opposite effects suggest
that two regulatory mechanisms may be involved in
the acute and chronic effects of LPS on airway E-
NTPDases.
Oxidative stress is one of the major causes of epi-
thelial injury in chronic lung diseases [74]. Reactive
oxygen and nitrogen species released from airway
epithelia or activated leukocytes damage cell mem-
branes by peroxidation of lipids, amino acids and car-
bohydrates. P aeruginosa LPS was reported to induce
their release from airway epithelia [75]. Incidentally,
intrahepatic cholestasis induced by intraperitoneal
injection of LPS reduced total liver NTPDase 1 ac-
tivity within 2 h [76]. In a rat model of glomerulopathy,
short-term exposure (1 h) to LPS inactivated endothe-
lial NTPDase 1, which was prevented by pre-treatment
with the anti-oxidant superoxide dismutase [77]. Oxi-
dative stress induced by membrane depolarization [78]
or ischemia/ reperfusion [79] also inhibited endothelial
NTPDase 1. Furthermore, short exposures (4 h) to the
pro-inﬂammatory cytokine, TNFa, inhibited endothe-
lial NTPDase 1, which was mimicked by hydrogen
peroxide but prevented by superoxide dismutase [80].
Altogether, these studies suggest that oxidative stress
may be responsible for the early and transient reduc-
tion in azide-sensitive E-NTPDase activities detected
in LPS-treated airway epithelia. Since the mRNA ex-
pression of E-NTPDases is unaffected by acute oxida-
tive stress [80] or LPS (Fig. 5B), and the inactivation of
NTPDase 1 by ischemia/reperfusion was prevented by
inhibitors of lipid peroxidation [79], the early loss of
surface activity may involve local peroxidation of mem-
brane lipids.
The long-term effects of LPS on the azide-sensitive
E-NTPDases have not been documented in mamma-
lian tissues. On the other hand, a 24 h exposure to
endotoxin stimulated NTPDase 2 on astrocytes [81], as
well as NS AP on endothelial, mesengial [82, 83] and
bronchial epithelial [73] cells. Additionally, the mRNA
expression of NTPDase 1 in rat forebrain was up-
regulated seven days after transient ischemia [84]. P.
aeruginosa LPS [85, 86] is well-known to inﬂuence
gene expression through the activation of the tran-
scription factors: Nuclear factor-kappa B and activator
protein-1 [87]. Recent studies have shown that CFTR
acts as a pattern recognition molecule for P. aerugi-
nosa LPS [88]. Endocytosis of the complex triggers
translocation of these transcription factors to the
nucleus, which initiates innate immunity through the
expression of numerous mediators recruiting and
activating inﬂammatory cells. These signaling path-
ways could be involved in the up-regulation of
NTPDase 1 and NTPDase 3 expression resulting from
long-term exposures to P. aeruginosa LPS in human
airways.
Adaptation of purine signaling to airway diseases
In past decade, the therapeutic potential of aerosolized
nucleotides for the treatment of chronic obstructive
lung diseases has motivated numerous studies on the
importance of purine signaling in the airways. This
elaborated cell communication system is involved in
major defense mechanisms including bacterial clear-
ance and inﬂammatory responses to bacterial infection.
Each signaling event constitutes a brief Fon-and-off_
switch mechanism allowing the target cells to perceive
the subsequent signal. Environmental changes are
communicated to target cells in the form of released
ATP, which binds surface receptors and triggers an
appropriate response. The efﬁciency of this communi-
cation system depends on the cells capacity to rapidly
eliminate these local bursts in extracellular ATP con-
centrations to prevent receptor desensitization. This
review establishes the pivotal role of E-NTPDases in
the regulation of airway defenses mediated by purine
signaling, namely bacterial clearance (Fig. 6). Cyclic
Fig. 5 Impact of P. aeruginisa LPS on NTPDase 1 and NTPDase
3. A The mucosal surface of primary bronchial epithelial
cultures were exposed 0, 1, 8 or 24 h to 100 ng/ml LPS, then
assayed for surface activity by high-pressure liquid chromatog-
raphy, as we previously described [10]. The activities of azide-
sensitive mucosal E-NTPDases measured with 0.03 mM ATP
were transiently reduced by LPS. B Quantiﬁcation of their
mRNA expression by real-time PCR using the house-keeping
gene 18S, as we previously described (89). LPS induced a
delayed increase in the expression level of both E-NTPDases
(N =5 ,* ,P < 0.05; Mann–Whitney test).
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clinical oscillatory devices, stimulates P2 receptor-
mediated MCC through ATP release and reduced
azide-sensitive E-NTPDase activities. We also pre-
sented original data indicating that NTPDase 1 and 3
activities and expressions are up-regulated in chronic
lung diseases by inﬂammatory mediators, including
endotoxin. Interestingly, P. aeruginosa LPS generated
a biphasic modulation of airway E-NTPDases which
may reconcile previous conﬂicting reports based on
exposure duration. Acute LPS exposures reduced E-
NTPDase activities, as observed during CCS, most
likelytoclearapathogenthroughP2receptor-mediated
MCC. The signaling pathways activated by P. aerugi-
nosa LPS and the lack of concomitant reduction in E-
NTPDase mRNA levels support a local inhibitory
mechanism that may involve oxidative stress-mediated
membrane damage. On the other hand, prolonged
endotoxin exposures mimicked the impact of chronic
lung diseases on NTPDases 1 and 3, characterized by
an up-regulation of both activities and mRNA expres-
sion. In chronically infected lungs, an increase in E-
NTPDase activities may represent an attempt to
prevent lung damage, excessive inﬂammation and P2
receptor desensitization by chronically elevated ATP
concentrations.
The information provided in this review also
exposes the complexity of the signaling interactions
taking place between different classes of mediators,
including bacterial products, cytokines and extracellu-
lar nucleotides, as combinations of mediators may
induce different responses than when tested individu-
ally. Furthermore, communication networks in the
airways may evolve with time during the establishment
of a chronic infection, as new target cells (bacteria,
leukocytes, lymphocytes) agglomerate on either side of
the epithelial barrier. It is proposed that nucleotide-
mediated airway functions deﬁned in normal tissues or
aseptic culture conditions may require reassessment
under conditions mimicking chronic lung diseases
before their therapeutic potential may be clearly
established.
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